Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 0.72 -2.20% -0.02
CTXR closed down 2.2 percent on Monday, March 18, 2024, on 1.61 times normal volume. It was able to find support at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Flat

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
50 DMA Support Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Upper Bollinger Band Touch Strength 0.00%
Gapped Down Weakness 0.00%
Crossed Above 50 DMA Bullish -2.20%
180 Bullish Setup Bullish Swing Setup -2.20%
Pocket Pivot Bullish Swing Setup -2.20%

   Recent Intraday Alerts

Alert Time
Possible Pocket Pivot about 12 hours ago
Reversed from Up about 13 hours ago
Rose Above Upper Bollinger Band about 15 hours ago
Up 1 ATR about 15 hours ago
Rose Above 20 DMA about 15 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Citius Pharmaceuticals, Inc. Description

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Drugs Inflammation Catheter Antibiotics Cancer Care Care Products Prescription Product Prescription Products Acetamides Bloodstream Infections Lidocaine

Is CTXR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.71
52 Week Low 0.6
Average Volume 675,845
200-Day Moving Average 0.86
50-Day Moving Average 0.72
20-Day Moving Average 0.74
10-Day Moving Average 0.72
Average True Range 0.05
RSI (14) 48.72
ADX 22.25
+DI 22.29
-DI 19.81
Chandelier Exit (Long, 3 ATRs) 0.70
Chandelier Exit (Short, 3 ATRs) 0.81
Upper Bollinger Bands 0.80
Lower Bollinger Band 0.69
Percent B (%b) 0.29
BandWidth 14.92
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram -0.0054
Fundamentals Value
Market Cap 114.49 Million
Num Shares 159 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -3.27
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.87
Resistance 3 (R3) 0.88 0.84 0.85
Resistance 2 (R2) 0.84 0.80 0.84 0.84
Resistance 1 (R1) 0.78 0.78 0.81 0.77 0.83
Pivot Point 0.74 0.74 0.76 0.74 0.74
Support 1 (S1) 0.68 0.70 0.71 0.67 0.61
Support 2 (S2) 0.64 0.68 0.64 0.60
Support 3 (S3) 0.58 0.64 0.60
Support 4 (S4) 0.57